Ames Gross shares his insights into the opportunities in Japan's API market in his latest article. Asia's active pharmaceutical ingredient (API) market is growing at a rapid pace. From 2008 to 2012, ...
Japan’s pharmaceutical industry is undergoing a period of transformation, and the contract development and manufacturing organization (CDMO) of large molecule active pharmaceutical ingredients (APIs) ...
Japan is legendary for its focus—many would say obsession—on producing high-quality products. When it comes to sourcing active pharmaceutical ingredients (APIs), Japanese generic drug firms are ...
Daiichi Sankyo will close an active pharmaceutical ingredients (API) plant in Hiratsuka, Japan, by September 2017. Opened in 1962, the facility employs 150 people and is one of Daiichi Sankyo’s four ...
The increase in the development of new drugs in Japan which will create opportunities for both international partners and domestic manufacturers of active pharmaceutical ingredients (APIs ) and ...
Tokyo, 11 March 2022: CPhI Japan 2022 returns as a SMART event – with live exhibition at the Big Sight Exhibition Center in Tokyo (20-22 April) alongside an online networking platform – as CPhI data[1 ...
The US Food and Drug Administration (FDA) this week released a warning letter sent to Okayama, Japan-based active pharmaceutical ingredient (API) manufacturer Daito Kasei Kogyo for releasing numerous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results